CD27 + CD38 hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients

Granulomatosis with polyangiitis (GPA) patients are prone to disease relapses. We aimed to determine whether GPA patients at risk for relapse can be identified by differences in B cell subset frequencies. Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1-6.3). Circ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2019, Vol.10, p.2221
Hauptverfasser: von Borstel, Anouk, Land, Judith, Abdulahad, Wayel H, Rutgers, Abraham, Stegeman, Coen A, Diepstra, Arjan, Heeringa, Peter, Sanders, Jan Stephan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Granulomatosis with polyangiitis (GPA) patients are prone to disease relapses. We aimed to determine whether GPA patients at risk for relapse can be identified by differences in B cell subset frequencies. Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1-6.3). Circulating B cell subset frequencies were analyzed by flow cytometry determining the expression of CD19, CD38, and CD27. B cell subset frequencies at the time of inclusion of future-relapsing (F-R) and non-relapsing (N-R) patients were compared and related to relapse-free survival. Additionally, CD27 CD38 B cells were assessed in urine and kidney biopsies from active anti-neutrophil cytoplasmic autoantibody-associated vasculitides (AAV) patients with renal involvement. Within 1.6 years, 30% of patients experienced a relapse. The CD27 CD38 B cell frequency at the time of inclusion was increased in F-R (median: 2.39%) compared to N-R patients (median: 1.03%; = 0.0025) and a trend was found compared with the HCs (median: 1.33%; = 0.08). This increased CD27 CD38 B cell frequency at inclusion was correlated to decreased relapse-free survival in GPA patients. In addition, 74.7% of patients with an increased CD27 CD38 B cell frequency (≥2.39%) relapsed during follow-up compared to 19.7% of patients with a CD27 CD38 B cell frequency of
ISSN:1664-3224